APP expands portfolio of injectable critical care products

APP Pharmaceuticals, LLC, a Fresenius Kabi Company, today announced it has acquired three products from Nexus Pharmaceuticals, Inc. Under terms of the agreement APP takes complete ownership of the products and becomes the Abbreviated New Drug Application (ANDA) holder for Benztropine Mesylate Injection, Levetiracetam Injection and Tranexamic Acid Injection.    

"The addition of these products broadens an already extensive portfolio of injectable APP critical care products," said John Ducker, president and chief executive officer of APP Pharmaceuticals. "As leaders in the reliable supply of sterile generic injectable drugs, APP will continue to identify, develop and market products to meet customer needs."

Benztropine Mesylate Injection, USP (1mg/mL, 2 mL) is therapeutically equivalent to the reference-listed drug Cogentin^®. Levetiracetam Injection (100 mg/ml, 5 mL) is therapeutically equivalent to the reference-listed drug Keppra^®. Tranexamic Acid Injection (100 mg/mL, 10 mL) is therapeutically equivalent to the reference-listed drug Cyklokapron®. According to IMS Health, in 2011 these three products combined represented a total market value of more than $90 million in the United States.